Krystal Biotech, Inc. Krystal Biotech, Inc.

Krystal Biotech, Inc.

KRYS

Clasificación en acciones #2124
Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on... Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier discovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania.
Precio por acción
$322.07
Última sincronización: 2026-10-21
Capitalización bursátil
$9.53B
Cambio (1 día)
-1.03%
Cambio (1 año)
72.76%
País
US
Comercio Krystal Biotech, Inc. (KRYS)

Categoría

Healthcare
Historial del precio de la acción de Krystal Biotech, Inc. (KRYS)
Precio más alto de cierre: $326.06 el 2026-10-01

Precio más bajo de cierre: $10.08 el 2017-09-01
Historial del precio de la acción de Krystal Biotech, Inc. desde 2017 hasta 2026
Desempeño anual del precio de la acción
Año Rendimiento
2026 (TTM) 20.87%
2025 39.10%
2024 50.07%
2023 49.77%
2022 7.69%
2021 22.40%
2020 -4.80%
2019 169.14%
2018 129.54%
2017 0.00%
Precio de la acción de empresas similares o competidoras
Empresa Precio de la acción Cambio 1a% País
$527.18 23.62%
US
$251.29 835.90%
US
$137.83 -3.78%
AU
$890.85 9.42%
NL
$758.21 7.77%
CH